← Back to Search

Non-Invasive Cardiac Monitoring for Pulmonary Hypertension

N/A

Waitlist Available

Led By Sonia Jasuja, M.D.

Research Sponsored by University of California, Los Angeles

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients with a confirmed diagnosis or suspected diagnosis of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) prior to initiation or change in therapy.

PAH or CTEPH patients undergoing right heart catheterization (RHC) as part of their standard of care.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months

Awards & highlights

Study Summary

This trial is researching new ways to measure risk and response to treatment in patients with PAH or CTEPH without invasive procedures. It will use non-invasive methods to measure cardiac output and stroke volume over the course of 1 year.

Who is the study for?

This trial is for adults over 18 with confirmed or suspected pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH). They must be undergoing a right heart catheterization as standard care and able to consent. It's not suitable for those with extreme body weights, certain heart valve issues, atrial fibrillation, or end-stage renal disease.Check my eligibility

What is being tested?

The study tests non-invasive methods to measure cardiac output and stroke volume in PAH/CTEPH patients at UCLA Medical Center. It aims to see if these measurements can help assess risk and monitor treatment response without invasive procedures. Participants will have follow-ups every three months for one year.See study design

What are the potential side effects?

Since the trial involves non-invasive measurement techniques, significant side effects are not expected. However, routine risks associated with right heart catheterization may apply but are part of standard care rather than specific to this study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have or might have high blood pressure in the lungs before starting or changing treatment.

Select...

I am a patient with PAH or CTEPH and will have a heart catheter test.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Bronchial Provocation Tests

cardiac index (CI)

Cardiac Output

+4 more

Secondary outcome measures

Nesiritide

World Health Organization (WHO)/New York Heart Association Functional Class (FC)

six-minute walk distance (6MWD)

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patients diagnosed with PAH or CTEPHExperimental Treatment1 Intervention

Patients with a confirmed diagnosis or suspected diagnosis of pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH) prior to initiation or change in therapy.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Non-invasive hemodynamic measurements

2018

N/A

~120

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor

1,528 Previous Clinical Trials

10,276,751 Total Patients Enrolled

5 Trials studying Pulmonary Arterial Hypertension

68 Patients Enrolled for Pulmonary Arterial Hypertension

Sonia Jasuja, M.D.Principal InvestigatorUniversity of California, Los Angeles

Media Library

Patients diagnosed with PAH or CTEPH Clinical Trial Eligibility Overview. Trial Name: NCT05618093 — N/A

Pulmonary Arterial Hypertension Research Study Groups: Patients diagnosed with PAH or CTEPH

Pulmonary Arterial Hypertension Clinical Trial 2023: Patients diagnosed with PAH or CTEPH Highlights & Side Effects. Trial Name: NCT05618093 — N/A

Patients diagnosed with PAH or CTEPH 2023 Treatment Timeline for Medical Study. Trial Name: NCT05618093 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment currently recruiting participants?

"Unfortunately, clinicaltrials.gov indicates that this trial is no longer recruiting participants; the details were first posted on December 5th 2022 and last modified on November 8th 2022. There are still 769 other trials enrolling patients at present though."

Answered by AI

Recent research and studies

CirculationJournal

Prognostic Value of Follow-up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension

Weatherald, Jason, Athénaïs Boucly, Denis Chemla, Laurent Savale, Mingkai Peng, Mitja Jevnikar, Xavier Jaïs, et al.. 2018. “Prognostic Value of Follow-up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension”. Circulation. Ovid Technologies (Wolters Kluwer Health). doi:10.1161/circulationaha.117.029254.

clinicaltrials.govStudy

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH

Sonia Jasuja, MD 2023. "Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05618093.

All > Pulmonary Arterial Hypertension > Pulmonary Hypertension